Targeting p31comet to Enhance Cisplatin-induced Cytotoxicity in Oral Squamous Cell Carcinoma Cells

Ana C. Henriques; João P.N. Silva; Bárbara Pinto; Patricia M. A.  Silva; Hassan Bousbaa

doi:10.48797/sl.2024.121

Authors

Ana C. Henriques UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal; Cell Biology of Viral Infection Lab, Instituto Gulbenkian de Ciência, 2780-156 Oeiras, Portugal https://orcid.org/0000-0002-4951-792X
João P.N. Silva UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0003-4455-4286
Bárbara Pinto UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0002-8804-6104
Patricia M. A. Silva UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal; Associate Laboratory i4HB –Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0002-0694-7321
Hassan Bousbaa UNIPRO – Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0002-4006-5779

DOI:

https://doi.org/10.48797/sl.2024.121

Keywords:

p31comet, cisplatin, combination therapy, cancer therapy, oral squamous cell carcinoma

Abstract

p31^comet plays a crucial role in silencing the spindle assembly checkpoint during mitosis. This study aimed to investigate whether p31^comet knockdown could enhance cisplatin-induced cytotoxicity in oral cancer cells. We assessed p31^comet expression in oral squamous cell carcinoma (OSCC) cells and examined the impact of p31^comet knockdown, cisplatin treatment, and their combination on OSCC cell viability and colony formation ability. Our findings indicated an upregulation of p31^comet at both mRNA and protein levels in OSCC cells compared with non-cancer cells. Knockdown of p31^comet amplified the inhibitory effects of cisplatin on OSCC cell viability and colony formation, particularly in cells more resistant to cisplatin. This suggests that exploring the combination of p31^comet inhibition and cisplatin could be a potentially promising strategy to enhance sensitivity of oral cancer cells to cisplatin.

References

Patel, B. V.; Hotaling, J.M. Impact of Chemotherapy on Subsequent Generations. Urol. Oncol. Semin. Orig. Investig. 2020, 38, 10–13, doi:10.1016/j.urolonc.2019.02.011.

Ghosh, S. Cisplatin: The First Metal Based Anticancer Drug. Bioorg. Chem. 2019, 88, 102925, doi:10.1016/j.bioorg.2019.102925.

Alqahtani, F.Y.; Aleanizy, F.S.; El Tahir, E.; Alkahtani, H.M.; AlQuadeib, B.T. Paclitaxel. Profiles Drug Subst. Excipients Relat. Methodol. 2019, 44, 205–238, doi:10.1016/bs.podrm.2018.11.001.

Zhang, J.; Ye, Z.; Tew, K.D.; Townsend, D.M. Cisplatin Chemotherapy and Renal Function. In; 2021; pp. 305–327.

Chow, L.Q.M. Head and Neck Cancer. N. Engl. J. Med. 2020, 382, 60–72, doi:10.1056/NEJMra1715715.

Johnson, D.E.; Burtness, B.; Leemans, C.R.; Lui, V.W.Y.; Bauman, J.E.; Grandis, J.R. Head and Neck Squamous Cell Carcinoma. Nat. Rev. Dis. Prim. 2020, 6, 92, doi:10.1038/s41572-020-00224-3.

Alfouzan, A.F. Radiation Therapy in Head and Neck Cancer. Saudi Med. J. 2021, 42, 247–254, doi:10.15537/smj.2021.42.3.20210660.

Bos, T.; Ratti, J.A.; Harada, H. Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer. Front. Oral Heal. 2021, 2, doi:10.3389/froh.2021.676643.

Cheng, Y.; Li, S.; Gao, L.; Zhi, K.; Ren, W. The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. Front. Oncol. 2021, 11, doi:10.3389/fonc.2021.761379.

Cocetta, V.; Ragazzi, E.; Montopoli, M. Mitochondrial Involvement in Cisplatin Resistance. Int. J. Mol. Sci. 2019, 20, 3384, doi:10.3390/ijms20143384.

Henriques, A.C.A.C.; Ribeiro, D.; Pedrosa, J.; Sarmento, B.; Silva, P.M.A.P.M.A.; Bousbaa, H. Mitosis Inhibitors in Anticancer Therapy: When Blocking the Exit Becomes a Solution. Cancer Lett. 2019, 440–441, 64–81, doi:10.1016/j.canlet.2018.10.005.

Topham, C.H.; Taylor, S.S. Mitosis and Apoptosis: How Is the Balance Set? Curr. Opin. Cell Biol. 2013, 25, 780–785, doi:10.1016/j.ceb.2013.07.003.

Dumontet, C.; Jordan, M.A. Microtubule-Binding Agents: A Dynamic Field of Cancer Therapeutics. Nat. Rev. Drug Discov. 2010, 9, 790–803, doi:10.1038/nrd3253.

Silva, P.M.A.; Ribeiro, N.; Lima, R.T.; Andrade, C.; Diogo, V.; Teixeira, J.; Florindo, C.; Tavares, Á.; Vasconcelos, M.H.; Bousbaa, H. Suppression of Spindly Delays Mitotic Exit and Exacerbates Cell Death Response of Cancer Cells Treated with Low Doses of Paclitaxel. Cancer Lett. 2017, 394, 33–42, doi:10.1016/j.canlet.2017.02.024.

Ma, H.T.; Chan, Y.Y.; Chen, X.; On, K.F.; Poon, R.Y.C. Depletion of P31comet Protein Promotes Sensitivity to Antimitotic Drugs. J. Biol. Chem. 2012, 287, 21561–21569, doi:10.1074/jbc.M112.364356.

Henriques, A.C.; Silva, P.M.A.; Sarmento, B.; Bousbaa, H. Antagonizing the Spindle Assembly Checkpoint Silencing Enhances Paclitaxel and Navitoclax-Mediated Apoptosis with Distinct Mechanistic. Sci. Rep. 2021, 11, 4139, doi:10.1038/s41598-021-83743-7.

Silva, P.M.A.; Delgado, M.L.; Ribeiro, N.; Florindo, C.; Tavares, Á.A.; Ribeiro, D.; Lopes, C.; Amaral, B.; Bousbaa, H.; Monteiro, L.S. Spindly and Bub3 Expression in Oral Cancer: Prognostic and Therapeutic Implications. Oral Dis. 2019, 25, 1291–1301, doi:10.1111/odi.13089.

Belur Nagaraj, A.; Kovalenko, O.; Avelar, R.; Joseph, P.; Brown, A.; Surti, A.; Mantilla, S.; DiFeo, A. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin. Cancer Res. 2018, 24, 4588–4601, doi:10.1158/1078-0432.CCR-17-2885.

Wu, M.; Wang, Y.; Yang, D.; Gong, Y.; Rao, F.; Liu, R.; Danna, Y.; Li, J.; Fan, J.; Chen, J.; et al. A PLK1 Kinase Inhibitor Enhances the Chemosensitivity of Cisplatin by Inducing Pyroptosis in Oesophageal Squamous Cell Carcinoma. EBioMedicine 2019, 41, 244–255, doi:10.1016/j.ebiom.2019.02.012.

Huang, L.; Li, W.; Dai, X.; Zhao, S.; Xu, B.; Wang, F.; Jin, R.-T.; Luo, L.; Wu, L.; Jiang, X.; et al. Biallelic Variants in MAD2L1BP (P31comet) Cause Female Infertility Characterized by Oocyte Maturation Arrest. Elife 2023, 12, doi:10.7554/eLife.85649.

Pagano, F.; Angelini, F.; Castaldo, C.; Picchio, V.; Messina, E.; Sciarretta, S.; Maiello, C.; Biondi-Zoccai, G.; Frati, G.; Meglio, F. di; et al. Normal versus Pathological Cardiac Fibroblast-Derived Extracellular Matrix Differentially Modulates Cardiosphere-Derived Cell Paracrine Properties and Commitment. Stem Cells Int. 2017, 2017, 1–9, doi:10.1155/2017/7396462.

Westhorpe, F.G.; Tighe, A.; Lara-Gonzalez, P.; Taylor, S.S. P31comet-Mediated Extraction of Mad2 from the MCC Promotes Efficient Mitotic Exit. J. Cell Sci. 2011, 124, 3905–3916, doi:10.1242/jcs.093286.

Wang, H.; Ma, Y. β-Elemene Alleviates Cisplatin Resistance in Oral Squamous Cell Carcinoma Cell via Inhibiting JAK2/STAT3 Pathway in Vitro and in Vivo. Cancer Cell Int. 2022, 22, 244, doi:10.1186/s12935-022-02650-7.

Li, J.; Vangundy, Z.; Poi, M. Cisplatin Induced the Expression of SEI1 (TRIP-Br1) Oncogene in Human Oral Squamous Cancer Cell Lines. Anticancer Res. 2020, 40, 67–73, doi:10.21873/anticanres.13926.

De Blasio, A.; Vento, R.; Di Fiore, R. Mcl‐1 Targeting Could Be an Intriguing Perspective to Cure Cancer. J. Cell. Physiol. 2018, 233, 8482–8498, doi:10.1002/jcp.26786.

Griffis, E.R.; Stuurman, N.; Vale, R.D. Spindly, a Novel Protein Essential for Silencing the Spindle Assembly Checkpoint, Recruits Dynein to the Kinetochore. J. Cell Biol. 2007, 177, 1005–1015, doi:10.1083/jcb.200702062.

Habu, T.; Matsumoto, T. P31comet Inactivates the Chemically Induced Mad2-Dependent Spindle Assembly Checkpoint and Leads to Resistance to Anti-Mitotic Drugs. Springerplus 2013, 2, 562, doi:10.1186/2193-1801-2-562.